James C Major1, Charles C Wykoff2, Daniel E Croft3, Rui Wang3, Angeline F Mariani3, Anna E Lehmann3, David M Brown1. 1. Retina Consultants of Houston, Weill Cornell Medical College, Houston Methodist Hospital. 2. Retina Consultants of Houston, Weill Cornell Medical College, Houston Methodist Hospital. Electronic address: ccwmd@houstonretina.com. 3. Retina Consultants of Houston, Houston, Tex.
Abstract
OBJECTIVE: Assess the efficacy of intravitreal aflibercept on pigment epithelial detachments (PED) associated with previously treated patients with neovascular age-related macular degeneration (AMD). DESIGN: Retrospective study. PARTICIPANTS: Sixty eyes. METHODS: Patients with persistent PED who were treated with intravitreal aflibercept (2.0 mg) with ≥2 previous injections of bevacizumab (1.25 mg) or ranibizumab (0.5 mg) were analyzed. RESULTS: Mean number of prior injections was 24.8 during a mean of 32 months of management (range 3-77 months). Baseline mean PED height was 258 µm (range 80-687 µm), which decreased at 1, 6, and 12 months upon switching to aflibercept to 226 µm (-14%, range 34-701 µm), 215 µm (-18%, range 0-666 µm), and 208 µm (-22%, range 0-752 µm), respectively. The majority of eyes experienced a decrease in PED height after switching to aflibercept: 50/58 (86%), 38/47 (81%), and 37/47 (79%) at months 1, 6, and 12, respectively. Reduction in PED height was weakly correlated with improved visual acuity (R(2) = 0.11). CONCLUSIONS: Intravitreal aflibercept resulted in significant reduction in PED height in previously treated eyes with neovascular AMD.
OBJECTIVE: Assess the efficacy of intravitreal aflibercept on pigment epithelial detachments (PED) associated with previously treated patients with neovascular age-related macular degeneration (AMD). DESIGN: Retrospective study. PARTICIPANTS: Sixty eyes. METHODS:Patients with persistent PED who were treated with intravitreal aflibercept (2.0 mg) with ≥2 previous injections of bevacizumab (1.25 mg) or ranibizumab (0.5 mg) were analyzed. RESULTS: Mean number of prior injections was 24.8 during a mean of 32 months of management (range 3-77 months). Baseline mean PED height was 258 µm (range 80-687 µm), which decreased at 1, 6, and 12 months upon switching to aflibercept to 226 µm (-14%, range 34-701 µm), 215 µm (-18%, range 0-666 µm), and 208 µm (-22%, range 0-752 µm), respectively. The majority of eyes experienced a decrease in PED height after switching to aflibercept: 50/58 (86%), 38/47 (81%), and 37/47 (79%) at months 1, 6, and 12, respectively. Reduction in PED height was weakly correlated with improved visual acuity (R(2) = 0.11). CONCLUSIONS: Intravitreal aflibercept resulted in significant reduction in PED height in previously treated eyes with neovascular AMD.